Superworth

Hyperfine EPS HYPR

Diluted earnings per share by quarter and over the last twelve months, from 2021.

Last 12 months, to Jun 30, 2026
−$0.38
Latest quarter, Q2 FY26
−$0.09
Fiscal year 2025
−$0.44

Hyperfine's earnings per share was −$0.38 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.09.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.44n/a
FY2024−$0.56n/a
FY2023−$0.62n/a
FY2022−$1.04n/a
FY2021−$25.05n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.09n/a−$0.38
Q1 FY26−$0.09n/a−$0.41
Q4 FY25−$0.06n/a−$0.44
Q3 FY25−$0.14n/a−$0.52
Q2 FY25−$0.12n/a−$0.52
Q1 FY25−$0.12n/a−$0.54
Q4 FY24−$0.14n/a−$0.56
Q3 FY24−$0.14n/a−$0.57
Q2 FY24−$0.14n/a−$0.58
Q1 FY24−$0.14n/a−$0.59
Q4 FY23−$0.15n/a−$0.62
Q3 FY23−$0.15n/a−$0.65

Against its peers

Companies in Healthcare nearest Hyperfine's size, closest first, today.

CompanyEPS, 12 monthsGrowth
HYPRHyperfine−$0.38
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ICCCImmucell$0.08−58% a year
KEQUKewaunee Scientific$2.76−33% a year
APTAlpha Pro Tech$0.41+24% a year
ATNMActinium Pharmaceuticals$0.36
NEPHNephros$0.16+33% a year
PDEXPro DEX$4.11+52% a year
PLXProtalix BioTherapeutics$0.23+283% a year
NATRNatures Sunshine Products$1.01+36% a year
Peer median$0.38

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Hyperfine

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.